GSK Bio
NEWS
Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.
As Brexit creeps closer and closer, the British government, as well as pharmaceutical companies and the European Medicines Agency, are preparing contingency plans for dealing with the possibility that healthcare-related companies will not have contracts in place in time.
AstraZeneca has seen another setback in a late-stage trial for chronic obstructive pulmonary disease (COPD) treatments. The latest stumbling block includes a failure for AstraZeneca’s investigational treatment to distinguish itself from a drug already marketed by rival GlaxoSmithKline.
Sensyne Health, a London-based healthcare artificial intelligence (AI) company founded by biotech entrepreneur Paul Drayson, recently launched an initial public offering (IPO) on the London AIM market. Drayson’s plan is to raise $78 million. It’s just one of many companies that are exploiting advances in computing, data science and AI to help identify and develop potential new drugs.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Four months after acquiring GlaxoSmithKline’s rare disease gene therapy portfolio, U.K.-based Orchard Therapeutics secured $150 million in an oversubscribed Series C funding round. The funds will be used to advance three late-stage programs that it gained from the deal with GSK.
GSK’s Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let’s take a look at some of those!
GlaxoSmithKline Chief Executive Officer Emma Walmsley has made another key appointment to her senior leadership team.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
JOBS
IN THE PRESS